Answers are grounded in this paper and cite their sources.
Background: Acute lung injury (ALI) is a severe inflammatory condition with substantial morbidity and mortality, with no approved pharmacologic therapies targeting its underlying inflammatory pathways. Prior studies demonstrated that intratracheal interleukin (IL)−10 reduces lipopolysaccharide (LPS)- and organic dust-induced lung and systemic inflammation. Methods: The present study evaluated the aerosol performance and efficacy of nebulized IL-10 against a high-dose LPS-induced ALI model with comparisons to shock-dose dexamethasone (5 mg/kg, intraperitoneal injections). C57BL/6 male mice were challenged with LPS (5 mg/mL) and treated with low- (0.1 mg/mL), mid- (0.5 mg/mL), or high-dose (1 mg/mL) IL-10, or vehicle, all by nose-only aerosol inhalation (15-minute exposure duration), with euthanasia on day 2. Results: Aerosolized IL-10 exhibited a mass median aerodynamic diameter of 1.66 µm (geometric standard deviation 2.04). Pulmonary deposited doses were 5.5–5.7 µg/mouse for LPS and 10.4, 21.3, and 38.4 (ug/kg) for low-, mid-, and high-dose IL-10. LPS-induced weight loss (18.6%) was reduced by high IL-10 (8.4%) and dexamethasone (7.0%), with no significant difference between treatments. Increased lung weights (40.8%) following LPS challenge were significantly reduced by mid- and high-dose IL-10 and dexamethasone. LPS-induced airway total cell and neutrophil counts in bronchoalveolar lavage fluid were not reduced by either treatment. In contrast, IL-10 treatment produced dose-dependent reductions in LPS-induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ, KC/CXCL1, MCP-1, and MIP-1α), with beneficial responses at the high IL-10 dose comparable to dexamethasone. Histopathology demonstrated dose-responsive reductions in LPS-induced peribronchovascular mixed cellular lung inflammation, significant at mid- and high IL-10 doses and comparable to dexamethasone. Conclusion: Overall, aerosolized IL-10 demonstrated aerodynamic properties consistent with deep lung penetration and dose-dependent efficacy at ≥21.3 µg/kg, achieving anti-inflammatory effects comparable with dexamethasone in this ALI murine model.
No takes yet. Share an insight, caveat, or question.
Poole et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: